Device Tl

Divergence-L Anterior/Oblique Lumbar Fusion System

Payments companies reported to CMS as associated with Divergence-L Anterior/Oblique Lumbar Fusion System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$220Kassociated payments (2023-2025)
85clinicians with associated payments
1company reporting

By year

2023 $120K
2024 $97K
2025 $2,585

Payments reported as associated with Divergence-L Anterior/Oblique Lumbar Fusion System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Orthopaedic Surgery of The Spine $72K
Neurological Surgery $49K
Surgery $39K
Orthopaedic Surgery $33K
Vascular Surgery $25K
Nurse Practitioner $538

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Divergence-L Anterior/Oblique Lumbar Fusion System

These are the largest totals companies reported as associated with Divergence-L Anterior/Oblique Lumbar Fusion System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Shane Burch San Francisco, CA Surgery $20,050.00
Sajjad Hussain Indianapolis, IN Vascular Surgery $20,000.00
Gregory Poulter Indianapolis, IN Orthopaedic Surgery of The Spine $20,000.00
Adrian Thomas Bedford, NH Orthopaedic Surgery of The Spine $18,533.03
Jared Seale Little Rock, AR Orthopaedic Surgery of The Spine $15,203.10
Charles Eichler San Francisco, CA Surgery $13,880.00
Daniel Silcox Atlanta, GA Orthopaedic Surgery $10,577.50
Michael Musacchio Evanston, IL Neurological Surgery $9,550.00
Martin Pham Los Angeles, CA Neurological Surgery $7,500.00
Michael Ghassibi Columbia, MO Orthopaedic Surgery $7,500.00

Prescribed Divergence-L Anterior/Oblique Lumbar Fusion System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.